Overall, these findings indicate that coordinated delivery of IFNα and IL-12 with TA significantly enhances TA-specific CD8+ T cell activation and tumor clearance without the need for MHC-II-restricted peptides in the delivered TA. The gene discussed is CD8A; the disease is neoplasm.